Achema middle east

Cryoport Continues its Expansion in the European Market with Tec4med Lifescience GmbH Acquisition

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
- Advertisement -

Cryoport, Inc., a leading global provider of innovative products and services to the fast-growing cell and gene therapy industry enabling the future of medicine for a new era of life sciences, announced the acquisition of Tec4med Lifescience GmbH, a solution provider and innovation leader in the pharmaceutical supply chain visibility, condition monitoring and temperature-controlled packaging space.

Tec4med was founded in 2017 by Nico Höler and Julian Poths as a technology spin-off of the Technical University of Darmstadt, Germany. Situated in the Frankfurt area, a global logistics hub for the pharmaceutical industry, Tec4med provides next generation pharmaceutical supply chain visibility by integrating condition monitoring, cloud and artificial intelligence (AI) solutions. ISO 9001-certified, Tec4med works with pharmaceutical-compliant, ready-to-use devices and intuitive easy-to-use software, offering customer-specific integrations to meet the rigorous standards of each individual client. Tec4med will continue to be run by the current management team.

“The acquisition of Tec4med is an important step for us in broadening our portfolio of condition monitoring solutions, fostering new product development and accelerating European market expansion, particularly in the DACH region (Germany, Austria, Switzerland),” commented Jerrell Shelton, CEO of Cryoport. “By integrating Tec4med’s innovative solutions and services across Cryoport’s family of companies, we will also expand our digital supply chain solutions offerings for the life sciences industry and provide our global clients even greater condition monitoring system options, logistics management capabilities and customer support.”

“The biopharmaceutical industry loses approximately $35 billion annually as a result of failures in temperature-controlled logistics. Adding Tec4med’s technology and project-based expertise will enhance Cryoport’s end-to-end supply chain solutions — including advanced real-time condition monitoring — and drive its digitization to provide our customers with full transparency within the pharmaceutical supply chain,” said Mark Sawicki, CEO of Cryoport Systems. “The Tec4med technology services will supplement and complement Cryoport’s existing services, bolstering the seamless integration of condition monitoring hardware and software throughout our solutions portfolio.”

Company: CryoPort Inc


Cryoport is a trusted global provider of solutions for maintaining temperature-sensitive life sciences commodities during distribution, serving the biopharmaceutical market with leading-edge logistics solutions for biologic materials, such as regenerative medicine, including immunotherapies, stem cells and CAR-T cells. Cryoport’s solutions are used by points-of-care, CRO’s, central laboratories, pharmaceutical companies, manufacturers, university researchers et al; as well as the reproductive medicine market, primarily in IVF and surrogacy; and the animal health market, primarily in the areas of vaccines and reproduction. Cryoport’s proprietary Cryoport Express® Shippers, Cryoportal® Logistics Management Platform, leading-edge SmartPak II™ Condition Monitoring System and geo-sensing technology, paired with unparalleled cold chain logistics expertise and 24/7 client support, make Cryoport the end-to-end cold chain logistics partner that the industry trusts.

Send Enquiry for this story

By submitting this form you agree to allow www.worldpharmatoday.com to contact you regarding your enquiry.
See our Privacy Policy to learn more.

Latest stories

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »